Immix Biopharma (IMMX) Reiterated at Market Outperform by Citizens on Interim Results for NEXICART-2 Trial

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $23.00 price target on Immix Biopharma, Inc. (NASDAQ: IMMX).

The analyst commented, "We reiterate our Market Outperform rating and price target of $23 for Immix Biopharma based on a revenue and earnings multiple analysis. Yesterday, Immix reported interim results based on all 45 patients treated in the NEXICART-2 trial, showcasing what we believe could be best-in-class results in relapsed/refractory AL amyloidosis. The company concurrently raised $125MM in an underwritten offering from dedicated marquee healthcare investors. Based on the conference call and the capital raised, we remain confident in the BLA submission for NXC-201 in 1H27. With a potential commercial launch in 2028, the initiation of a front-line study slated for 2027, and a solid cash position of $357.1MM (proforma), we believe Immix represents an attractive investment opportunity and continue to be buyers amidst the current weakness in shares."

For an analyst ratings summary and ratings history on Immix Biopharma, Inc. click here. For more ratings news on Immix Biopharma, Inc. click here.

Shares of Immix Biopharma, Inc. closed at $10.54 yesterday.

You May Also Be Interested In

• Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
• William Blair Downgrades Fidelity National Information Services (FIS) to Market Perform
• RxSight Inc. (RXST) PT Lowered to $5 at Stifel